Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601134 | 1.00 | KDM4E (0.53) | KDM4ENPC1RAB9ASMYD3POLB | |
| SCHEMBL3603432 | 0.93 | KDM4E (0.51) | KDM4ENPC1RAB9ASMYD3POLB | |
| SCHEMBL3603434 | 0.93 | KDM4E (0.51) | KDM4ENPC1RAB9ASMYD3POLB | |
| SCHEMBL17206290 | 0.87 | KDM4E (0.60) | KDM4ENPC1RAB9ASMYD3POLB | |
| SCHEMBL19837635 | 0.85 | KDM4E (0.57) | KDM4ENPC1RAB9ASMYD3POLB | |
| SCHEMBL3605675 | 0.84 | SMYD3 (0.50) | RAB9ASMYD3KDM1AKDRPARP1 | |
| SCHEMBL3611578 | 0.84 | SMYD3 (0.50) | RAB9ASMYD3KDM1AKDRPARP1 | |
| SCHEMBL3605671 | 0.84 | SMYD3 (0.50) | RAB9ASMYD3KDM1AKDRPARP1 | |
| SCHEMBL17205073 | 0.84 | TAS1R3 (0.59) | KDM4ENPC1RAB9ASMYD3POLB | |
| SCHEMBL15506757 | 0.84 | TAS1R3 (0.59) | KDM4ENPC1RAB9ASMYD3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | KDM4E 963/4885NPC1 1710/4885RAB9A 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.